{"id":502578,"date":"2026-06-16T14:00:10","date_gmt":"2026-06-16T14:00:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/502578\/"},"modified":"2026-06-16T14:00:10","modified_gmt":"2026-06-16T14:00:10","slug":"most-people-who-stop-glp-1-drugs-like-ozempic-eventually-return","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/502578\/","title":{"rendered":"Most people who stop GLP-1 drugs like Ozempic eventually return"},"content":{"rendered":"<p id=\"first\">People taking GLP-1 medications for type 2 diabetes (liraglutide, semaglutide, or tirzepatide) may be more likely to stop and later restart treatment than many people realize, according to research presented Sunday at ENDO 2026, the Endocrine Society&#8217;s annual meeting in Chicago, Ill.<\/p>\n<p>The study examined two questions that have received limited attention so far.<\/p>\n<p>&#8220;Our study asked two questions that haven&#8217;t been well answered until now: How many people with type 2 diabetes taking GLP-1 medications actually stop using them? And how many restart them?&#8221; said Sainikhil Sontha, M.S., a research associate at Boston University School of Public Health in Boston, Mass.<\/p>\n<p>Researchers analyzed Komodo Health U.S. claims data (January 2019 to June 2025) in a retrospective cohort study. The analysis included adults ages 18 to 64 with type 2 diabetes and a BMI \u226525 kg\/m2 who had started treatment with liraglutide (Victoza), semaglutide (Ozempic), or tirzepatide (Mounjaro). Participants had been enrolled during the previous year and had more than 6 months of follow-up data available.<\/p>\n<p>The team defined discontinuation as a gap of more than 60 days between prescription refills. Restarting treatment after such a gap was classified as reinitiation.<\/p>\n<p>GLP-1 Discontinuation Rates in Type 2 Diabetes<\/p>\n<p>&#8220;Using insurance records from more than 60,000 Americans with type 2 diabetes, we found that about 4 in 10 patients stopped their GLP-1 medication within the first year, and nearly 6 in 10 had stopped by the end of two years,&#8221; Sontha said.<\/p>\n<p>The researchers also uncovered a more encouraging trend.<\/p>\n<p>&#8220;More than half of those who stopped restarted therapy within a year (41.5%), and nearly two-thirds did so within two years (58%),&#8221; Sontha said. &#8220;This suggests that for many patients, these medications aren&#8217;t being abandoned permanently; use is more start-and-stop than most people assumed.&#8221;<\/p>\n<p>To better understand what influences treatment patterns, the researchers used Cox proportional hazards models and examined sociodemographic, clinical and provider-level factors.<\/p>\n<p>Who Is More Likely To Stop GLP-1 Medications?<\/p>\n<p>According to the findings, people covered by Medicaid or Medicare, Black patients, and those who experienced nausea or other gastrointestinal side effects (37%) were more likely to discontinue a GLP-1 medication within the first year.<\/p>\n<p>The study also found that patients whose first GLP-1 prescription came from an endocrinologist were 10% less likely to stop treatment.<\/p>\n<p>Newer GLP-1 Drugs Linked to Better Persistence<\/p>\n<p>Medication type also appeared to make a difference.<\/p>\n<p>People taking newer GLP-1 drugs such as tirzepatide were 41% less likely to discontinue treatment than those using older medications such as liraglutide. Users of semaglutide were 28% less likely to discontinue anti-obesity medication use compared with people taking older drugs.<\/p>\n<p>Why Staying on GLP-1 Therapy Matters<\/p>\n<p>&#8220;This research matters because consistent use of these medications is what produces their protective effects,&#8221; Sontha said. &#8220;Stopping early may mean missed opportunities to prevent heart attacks, kidney disease progression and other complications.&#8221;<\/p>\n<p>Researchers say the results may help healthcare providers, insurers and policymakers identify patients who could benefit from additional support to remain on GLP-1 therapy over time, Sontha said.<\/p>\n","protected":false},"excerpt":{"rendered":"People taking GLP-1 medications for type 2 diabetes (liraglutide, semaglutide, or tirzepatide) may be more likely to stop&hellip;\n","protected":false},"author":2,"featured_media":486251,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60,214960],"class_list":["post-502578","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland","tag-kidney-disease-todayamp039s-healthcare-heart-disease-diabetes-obesity-diseases-and-conditions-health-policy-hormone-disorders"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/502578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=502578"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/502578\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/486251"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=502578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=502578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=502578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}